Health care costs for treatment of disseminated breast cancer

European Journal of Cancer

Volumn 45, Issue 11, 2009, Pages 1987-1991

  Dahlberg, L ^a   Lundkvist, J ^b,c   Lindman, H ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Novartis Sweden   (Sweden)

Author keywords

Breast cancer; Costs; Metastatic; Sweden

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; COHORT ANALYSIS; COST OF ILLNESS; DISSEMINATED CANCER; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HORMONAL THERAPY; HOSPITAL CARE; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; LENGTH OF STAY; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MEDICAL EXAMINATION; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; SWEDEN;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DRUG COSTS; FEMALE; GENES, ERBB-2; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PALLIATIVE CARE; RETROSPECTIVE STUDIES; SWEDEN;

EID: 67649354224     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.03.023     Document Type: Article

References (9)

1. Lidgren M., Wilking N., and Jonsson B. Cost of breast cancer in Sweden in 2002. Eur J Health Econ 8 1 (2007) 5-15
2. Lidgren M., Wilking N., Jönsson B., and Rehnberg C. Resource use and costs associated with different states of breast cancer. Int J Technol Assess Health Care 23 2 (2007) 223-231
3. Remak E., and Brazil L. Cost of managing women presenting with stage IV breast cancer in the United Kingdom. Br J Cancer 91 1 (2004) 77-83
4. Will B.P., Berthelot J.M., Le Petit C., Tomiak E.M., Verma S., and Evans W.K. Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer 36 6 (2000) 724-735
5. Berkowitz N., Gupta S., and Silberman G. Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value Health 3 1 (2000) 23-30
6. Jakobsson T. Resource use in administration of chemotherapy. Thesis, Uppsala University, 2005.
7. Jönsson B., and Wilking N. A global comparison regarding patient access to cancer drugs. Ann Oncol 18 Suppl. 3 (2007)
8. Lidgren M., Jönsson B., Rehnberg C., Willking N., and Bergh J. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol 19 3 (2008) 487-495
9. Delea T.E., El-Ouagari K., Karnon J., and Sofrygin O. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. Breast Cancer Res Treat 108 3 (2008) 375-387